Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- Chlamydia trachomatis infections of the adult.in: Holmes K.K. Sparling P.F. Stamm W.E. Sexually Transmitted diseases. 4th ed. McGraw-Hill, New York2008: 575
- Epidemiologic differences between chlamydia and gonorrhea.Am J Public Health. 1990; 80: 1338-1342
- What are the consequences of relying upon self-reports of sexually transmitted diseases? Lessons learned about recanting in a longitudinal study.J Adolesc Health. 2009; 45: 187-192
- Are adolescents accurate in self-report of frequencies of sexually transmitted diseases and pregnancies?.J Adolesc Health. 1997; 21: 91-96
- Validity of self-reported sexually transmitted diseases among African American female adolescents participating in an HIV/STD prevention intervention trial.Sex Transm Dis. 2001; 28: 468-471
- Data collection for sexually transmitted disease diagnoses: a comparison of self-report, medical record reviews, and state health department reports.Ann Epidemiol. 2005; 15: 236-242
- Current methods of laboratory diagnosis of Chlamydia trachomatis infections.Clin Microbiol Rev. 1997; 10: 160-184
- The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.Am J Obstet Gynecol. 2010; 203: 115.e1-115.e7
- Serodiagnosis of Chlamydia trachomatis infection with the microimmunofluorescence test.in: Hobson D. Holmes K. Nongonococcal urethritis and related infections. American Society for Microbiology, Washington (DC)1977: 237-248
- Chlamydial antigens stabilized with formalin for use in the micro-immunofluorescence test.J Clin Microbiol. 1980; 12: 409-412
- How to use Chlamydia antibody testing in subfertility patients.Hum Reprod. 1998; 13: 1094-1098
- The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis.Fertil Steril. 1997; 67: 1031-1037
- Understanding interobserver agreement: the kappa statistic.Fam Med. 2005; 37: 360-363
US Preventive Services Task Force. Final recommendation statement: Chlamydia and gonorrhea: screening. US Preventive Services Task Force; 2014. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/chlamydia-and-gonorrhea-screening. Accessed August 2016.
- Sexually transmitted disease testing misconceptions threaten the validity of self-reported testing history.Public Health Nurs. 2013; 30: 117-127
- Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project.Contraception. 2011; 84: 493-498
- Sexually transmitted disease surveillance 2014.US Department of Health and Human Services, Atlanta2015
- Change in sexual behavior with provision of no-cost contraception.Obstet Gynecol. 2014; 123: 771-776
- Chlamydia antibody testing in screening for tubal factor subfertility: the significance of IgG antibody decline over time.Hum Reprod. 2002; 17: 699-703
- Persistence of antichlamydial antibodies after treatment of acute salpingitis with doxycycline.Eur J Obstet Gynecol Reprod Biol. 1993; 48: 117-121
- Persistence of chlamydial antibodies after pelvic inflammatory disease.J Clin Microbiol. 1986; 23: 924-928
Present addresses include the following: Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, NY (Dr Frisse); St Louis County Department of Public Health, St Louis, MO (Mr Tutlam); and Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN (Dr Peipert).
The views expressed herein are those of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health.
The funding sources had no role in the study design or the collection, analysis, and interpretation of data. They had no role in the writing of the report or in the decision to submit this article for publication.
The Contraceptive CHOICE Project is supported by the Susan T. Buffett Foundation. This research was also supported in part by grants from Bayer Healthcare Pharmaceuticals, Teva (WHC-2013-7), and a Clinical and Translational Science Award (UL1RR024992) from the National Institutes of Health.
Dr Peipert receives research support from Bayer , Teva , and Merck and serves on advisory boards for Teva and Perrigo. Dr Marrazzo serves on advisory boards for Cepheid and Perrigo. Dr Schreiber receives research funding from Medicines 360. The University of Utah Department of Obstetrics and Gynecology Program in Family Planning receives research funding from Bayer, Bioceptive, Contramed, Medicines 360, Merck, and Teva. Dr Turok serves on advisory boards for Bayer, Teva, Pharmanest, and Allergan; he is a consultant for Bioceptive and a speaker for Allergan, Medicines 360, Merck, and Teva. The other authors report no conflict of interest.
Cite this article as: Frisse AC, Marrazzo JM, Tutlam NT, et al. Validity of self-reported history of Chlamydia trachomatis infection. Am J Obstet Gynecol 2017;216:393.e1-7.